Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azenosertib in Recurrent or Persistent Uterine Serous Carcinoma
NCT06369155Phase 2Recruiting
- Start
- Mar 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azenosertib in uterine serous carcinoma (USC). Primary endpoints: Percentage Change in Replication Fork Speed in Overall Response at 7 months and Percentage Change in Replication Fork Speed in 6 Month Progression Free Survival. Started Mar 2025; status: recruiting.
02
Drugs
azenosertib
03
Conditions
uterine serous carcinoma (USC)
Beyond the preview
Go deeper on NCT06369155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06369155.